NASDAQ:ASBP 11 November 2025 - 15 December 2025

Aspire Biopharma Holdings, Inc. is stepping into December 15, 2025 with a very “micro-cap biotech” mix of catalysts and pressure points: a Nasdaq deadline calendar, an FDA regulatory milestone for its lead sublingual aspirin program, and capital-structure dynamics that can swing sentiment fast.

Micro‑cap biotech Aspire Biopharma Holdings, Inc. is back in the spotlight today after securing a new $100 million equity line of credit and releasing its Q3 2025 10‑Q, sending the stock sharply higher in pre‑market trading.

Trading in Aspire Biopharma swung sharply. A pre‑market “health‑care movers” screen showed ASBP briefly up more than 30%, before regular‑session selling pulled shares lower on very heavy volume. Mid‑session, ASBP was down roughly 20–25% versus Monday’s close, with an exceptionally wide intraday range—characteristic of micro‑cap names facing near‑term listing and financing milestones. Benzinga